Please forward this error screen to 162. Can be in any position in the term and matches any number of characters. Search terms pleural fluid analysis
Please forward this error screen to 162. Can be in any position in the term and matches any number of characters. Search terms pleural fluid analysis normal values pdf be a single word or several words.
Quotes can be used to search for phrases. This information should not be considered all-inclusive or applicable to all clinical scenarios. For each analyte, separate entries for individual body fluids are included. Information should be interpreted with caution and in the context of the instrumentation used because the literature sources consist of studies across many decades, analyzers, and reagent formulations. All information should be viewed in the context of the patient’s clinical presentation.
Body fluid tumor markers should NOT be used as sole evidence of malignancy for diagnostic purposes and should be reviewed in correlation with cytology, serum results, and other clinical evidence. This website will be updated with additional assays, reference intervals and interpretive guidance, and references as information becomes available. Utility of pericardial fluid tumor marker testing for the differentiation of malignant from benign pericardial effusions is not well-defined. Body fluid tumor markers should NOT be used as sole evidence of malignancy for diagnostic purposes, and should be reviewed in correlation with cytology, serum results, and other clinical evidence. Limited published data exists regarding pericardial fluid AFP.
Adler Y, Charron P, Imazio M, et al. Maisch B, Seferović PM, Ristić AD, Erbel R, Rienmüller R, Adler Y, Tomkowski WZ, Thiene G, Yacoub MH. Guidelines on the diagnosis and management of pericardial diseases executive summary. The Task Force on the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology. Body fluid AFP concentrations may provide supportive information regarding the etiology of potential malignant serous effusions with hepatocellular carcinoma. AFP have been observed with hepatocellular carcinoma. Serum specimens, however, have shown higher concentrations of AFP than the corresponding peritoneal fluid specimen.
Including cytology findings increased sensitivity to 59. Results should be reviewed in correlation with cytology, serum results, and other clinical evidence. Cascinu S, Del Ferro E, Barbanti I, Ligi M, Fedeli A, Catalano G. Tumor markers in the diagnosis of malignant serous effusions. Runyon BA, Hoefs JC, Morgan TR.
Ascitic fluid analysis in malignancy-related ascites. Salerno F, Restelli B, Incerti P, Annoni G, Capozza L, Badalamenti S, Lampertico P, Mojana E, Moser P, Tommasini M. Utility of ascitic fluid analysis in patients with malignancy-related ascites. Kaleta EJ, Tolan NV, Ness KA, O’Kane D, Algeciras-Schimnich A.
CEA, AFP and CA 19-9 analysis in peritoneal fluid to differentiate causes of ascites formation. Supportive evidence in the evaluation of suspected malignancy-associated pleural effusion. Meta-analyses do not support the routine use of single tumor markers for the diagnosis of malignant pleural effusions. British Thoracic Society 2010 pleural disease guideline states that pleural fluid tumor markers do not have a role in the routine analysis of pleural effusions.